- Home
- CGON vs ATRC Comparison
CGON vs ATRC Comparison
Compare CGON & ATRC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CGON
- ATRC
- Stock Information
- Founded
- CGON 2010
- ATRC 2000
- Country
- CGON United States
- ATRC United States
- Employees
- CGON N/A
- ATRC N/A
- Industry
- CGON
- ATRC Medical/Dental Instruments
- Sector
- CGON
- ATRC Health Care
- Exchange
- CGON NYSE
- ATRC Nasdaq
- Market Cap
- CGON 1.3B
- ATRC 1.5B
- IPO Year
- CGON 2024
- ATRC 2005
- Fundamental
- Price
- CGON $20.64
- ATRC $32.01
- Analyst Decision
- CGON Strong Buy
- ATRC Strong Buy
- Analyst Count
- CGON 10
- ATRC 10
- Target Price
- CGON $65.11
- ATRC $48.50
- AVG Volume (30 Days)
- CGON 1.3M
- ATRC 556.9K
- Earning Date
- CGON 05-08-2025
- ATRC 04-29-2025
- Dividend Yield
- CGON N/A
- ATRC N/A
- EPS Growth
- CGON N/A
- ATRC N/A
- EPS
- CGON N/A
- ATRC N/A
- Revenue
- CGON $1,139,000.00
- ATRC $465,307,000.00
- Revenue This Year
- CGON N/A
- ATRC $14.60
- Revenue Next Year
- CGON $16,237.24
- ATRC $12.58
- P/E Ratio
- CGON N/A
- ATRC N/A
- Revenue Growth
- CGON 461.08
- ATRC 16.55
- 52 Week Low
- CGON $14.80
- ATRC $18.94
- 52 Week High
- CGON $46.99
- ATRC $43.11
- Technical
- Relative Strength Index (RSI)
- CGON 43.38
- ATRC 43.87
- Support Level
- CGON $19.47
- ATRC $29.48
- Resistance Level
- CGON $20.63
- ATRC $33.56
- Average True Range (ATR)
- CGON 2.07
- ATRC 2.13
- MACD
- CGON 0.20
- ATRC 0.14
- Stochastic Oscillator
- CGON 48.59
- ATRC 52.38
About CGON CG ONCOLOGY INC
CG Oncology Inc is a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients afflicted with bladder cancer. The company's lead candidate, cretostimogene grenadenorepvec, is a targeted oncolytic intravesically delivered immunotherapy agent that is in two phase three trials (one high-risk BCG unresponsive NMIBC trial and one intermediate-risk NMIBC trial) and a phase two clinical study with a checkpoint inhibitor for high-risk BCG unresponsive NMIBC disease.
About ATRC AtriCure Inc.
AtriCure Inc is an innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management and sells its products to medical centers through its direct sales force and distributors. Its product line includes Cryo, Soft Tissue Dissection, RF Ablation Pacing and Sensing, and others. The company also offers a variety of minimally invasive ablation devices and access tools to facilitate the growing trend in less invasive cardiac and thoracic surgery. Geographically, it generates a majority of its revenue from the United States.